Jeevan Scientific Technology Limited (JSTL) has announced plans to raise Rs 30.74 crore through a preferential issue of convertible warrants and equity shares. The company's board has approved the issuance of 35 lakh convertible warrants and 41.85 lakh equity shares to promoters and non-promoters, as per a notice for an Extraordinary General Meeting (EGM) scheduled for November 12, 2025.

Capital Restructuring Details

• JSTL plans to increase its authorized share capital from Rs 21.00 crore to Rs 25.00 crore.
• The company will issue 35 lakh convertible warrants at Rs 40.00 per warrant to promoters and non-promoters, raising Rs 14.00 crore.
• Additionally, 41.85 lakh equity shares will be issued at Rs 40.00 per share to non-promoters, raising Rs 16.74 crore.
• The total fundraising amounts to Rs 30.74 crore.

Utilization of Funds

The company intends to use the raised capital for the following purposes:

Key Points of the Preferential Issue

• The issue price of Rs 40.00 per share includes a premium of Rs 30.00 over the face value of Rs 10.00.
• The relevant date for pricing is October 13, 2025.
• Warrants will be convertible into equity shares within 18 months from the date of allotment.
• The preferential issue is subject to shareholder approval at the EGM.

Additional Corporate Actions

JSTL also plans to:

• Adopt a new Memorandum of Association under the Companies Act 2013.
• Change its registered office state from Andhra Pradesh to Telangana.

Voting and Participation Details

• The EGM will be held through Video Conference / Other Audio-Visual Means.
• The cut-off date for e-voting is November 5, 2025.
• Shareholders can join the EGM 15 minutes before and after the scheduled time.

This capital restructuring move by Jeevan Scientific Technology Limited aims to strengthen its financial position and support long-term growth initiatives. Shareholders will have the opportunity to vote on these proposals at the upcoming EGM.

Jeevan Scientific Technology Limited (JSTL) has announced a significant capital raising initiative, as approved by its Board of Directors on October 15, 2025. The company plans to raise approximately Rs. 30.74 crore through a combination of convertible warrants and equity share issuances.

Key Highlights of the Capital Raising Plan

1. Convertible Warrants Issue:

   • Up to 35,00,000 convertible warrants to be issued
   • Issue price: Rs. 40.00 per warrant
   • Total amount to be raised: Rs. 14.00 crore
   • Allotted to both promoters and non-promoters

2. Equity Shares Issue:

   • Up to 41,85,000 equity shares to be issued
   • Issue price: Rs. 40.00 per share
   • Total amount to be raised: Rs. 16.74 crore
   • Allotted exclusively to non-promoters

Detailed Breakdown of the Proposed Allotment

Convertible Warrants Allotment

Top Equity Shares Allottees (Non-Promoters)

Additional Corporate Actions

1. Increase in Authorized Share Capital:

   • From Rs. 21.00 crore to Rs. 25.00 crore
   • New structure: 2,50,00,000 equity shares of Rs. 10.00 each

2. Adoption of New Memorandum of Association:

   • To align with the Companies Act, 2013

3. Committee Reconstitution:

   • Audit, Nomination and Remuneration, Stakeholder Relationship, Risk Management, and Corporate Social Responsibility committees have been reconstituted

Shareholder Approval and Regulatory Compliance

• An Extraordinary General Meeting (EGM) is scheduled for November 12, 2025, to seek shareholder approval for these proposals
• The preferential allotment is subject to regulatory approvals

Impact on Shareholding Pattern

Post-allotment, assuming full subscription and conversion of warrants:

• Promoters' holding: 90,24,585 equity shares (38.37%)
• Public holding: 1,44,94,380 equity shares (61.63%)

This capital raising initiative by Jeevan Scientific Technology Limited represents a strategic move to strengthen its financial position. The company's decision to offer a significant portion of the new securities to non-promoters could potentially lead to a more diverse shareholder base. Investors and market watchers will be keenly observing the outcome of the upcoming EGM and the subsequent steps in this capital raising process.